H-Leu-Ser-Lys-Leu-OH trifluoroacetate salt
Modify Date: 2025-09-23 11:24:29
H-Leu-Ser-Lys-Leu-OH trifluoroacetate salt structure
|
Common Name | H-Leu-Ser-Lys-Leu-OH trifluoroacetate salt | ||
|---|---|---|---|---|
| CAS Number | 162559-45-7 | Molecular Weight | 459.58000 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C21H41N5O6 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of H-Leu-Ser-Lys-Leu-OH trifluoroacetate saltH-Leu-Ser-Lys-Leu-OH (LSYL) is a latency-associated peptide at the amino terminus of LAP, with inhibitory effect on TGF-β1 activation. H-Leu-Ser-Lys-Leu-OH, binding with KRFK (HY-P3970), can block the signal transduction of TGF-β1, and prevent the progression of hepatic damage and fibrosis[1]. |
| Name | h-leu-ser-lys-leu-oh |
|---|
| Description | H-Leu-Ser-Lys-Leu-OH (LSYL) is a latency-associated peptide at the amino terminus of LAP, with inhibitory effect on TGF-β1 activation. H-Leu-Ser-Lys-Leu-OH, binding with KRFK (HY-P3970), can block the signal transduction of TGF-β1, and prevent the progression of hepatic damage and fibrosis[1]. |
|---|---|
| Related Catalog | |
| Target |
TGF-β1[1] |
| In Vitro | H-Leu-Ser-Lys-Leu-OH (LSKL) 也可以阻断 TSP-1 对 TGF-β1 的激活，并降低 KRFK 肽对 TGF-β1 的激活[1]。 |
| In Vivo | H-Leu-Ser-Lys-Leu-OH (LSKL) (100 μg/0.5 mL; 腹腔注射; 每日给药，共 4 周; 并伴随着 DMN 的处理) 能够保护二甲基亚硝胺 (DMN) 处理 (10 mg/kg; 腹腔注射; 每周连续3天给药, 共 4 周) 导致的大鼠肝萎缩。H-Leu-Ser-Lys-Leu-OH 还可以预防肝损伤和纤维化的进展[1]。 |
| References |
| Molecular Formula | C21H41N5O6 |
|---|---|
| Molecular Weight | 459.58000 |
| Exact Mass | 459.30600 |
| PSA | 196.87000 |
| LogP | 1.63950 |
| WGK Germany | 3 |
|---|